Robbins Farley Purchases 9,465 Shares of iShares Biotechnology ETF $IBB

Posted by George Bondi on Oct 21st, 2026

Robbins Farley purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 9,465 shares of the financial services provider’s stock, valued at approximately $1,993,000.

Other large investors have also recently added to or reduced their stakes in the company. Kaydan Wealth Management Inc. grew its position in shares of iShares Biotechnology ETF by 3.9% in the 3rd quarter. Kaydan Wealth Management Inc. now owns 1,363 shares of the financial services provider’s stock valued at $287,000 after acquiring an additional 51 shares during the period. Carter Financial Group INC. increased its stake in shares of iShares Biotechnology ETF by 2.2% during the 2nd quarter. Carter Financial Group INC. now owns 2,423 shares of the financial services provider’s stock worth $461,000 after purchasing an additional 53 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of iShares Biotechnology ETF by 8.8% during the 1st quarter. Parallel Advisors LLC now owns 744 shares of the financial services provider’s stock worth $126,000 after purchasing an additional 60 shares during the last quarter. Community Bank N.A. increased its stake in shares of iShares Biotechnology ETF by 5.2% during the 2nd quarter. Community Bank N.A. now owns 1,483 shares of the financial services provider’s stock worth $282,000 after purchasing an additional 73 shares during the last quarter. Finally, Valmark Advisers Inc. raised its holdings in shares of iShares Biotechnology ETF by 3.2% in the 1st quarter. Valmark Advisers Inc. now owns 2,435 shares of the financial services provider’s stock valued at $411,000 after purchasing an additional 75 shares during the period. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 3.2%

Shares of IBB stock opened at $210.50 on Wednesday. The firm’s 50-day moving average is $207.26 and its 200-day moving average is $188.59. iShares Biotechnology ETF has a 52-week low of $153.25 and a 52-week high of $217.12.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 18th. Investors of record on Tuesday, September 15th were issued a dividend of $0.0112 per share. The ex-dividend date was Tuesday, September 15th. This is a decrease from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238. This represents a $0.04 dividend on an annualized basis and a yield of 0.0%.

iShares Biotechnology ETF Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.